Clinical Trial Update: GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GS-5885 (ledipasvir), GS-9451, tegobuvir, and ribavirin in interferon-ineligible or intolerant subjects with chronic genotype 1 hepatit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• GS-5885 (GS-5885)
• GS-9451 (GS-9451)
• Ribavirin (ribavirin)
• Tegobuvir (Tegobuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Genotype 1a or 1b HCV Infection | Phase 2 | Status: COMPLETED